← All trials
NCT07243704
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2026
- Primary completion
- Oct 31, 2028
- Completion date
- Oct 31, 2028
- First posted
- Nov 24, 2025
- Last posted
- Nov 24, 2025
- Enrollment
- 5676
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Christian Medical College, Vellore, IndiaLead sponsor
- Christian Medical College, Vellore, IndiaSponsor investigator
- Rangaraya Medical CollegeCollaborator
- King George's Medical UniversityCollaborator
- Amrita Institute of Medical SciencesCollaborator
- Narayana Hrudayalaya LimitedCollaborator
- Christian Medical College, Vellore, IndiaOfficial
- Christian Medical College, Vellore, IndiaCollaborator
- Indian Council of Medical ResearchCollaborator
- Kasturba Medical CollegeCollaborator
- All India Institute of Medical SciencesCollaborator
- All India Institute of Medical SciencesCollaborator
- Baptist Christian Hospital, Tezpur, IndiaCollaborator
- Bharati Vidyapeeth UniversityCollaborator
- Government General Hospital Guntur, IndiaCollaborator
- Government Medical College, IndiaCollaborator
- Guru Gobind Singh Medical CollegeCollaborator
- Banaras Hindu UniversityCollaborator
- KG Hospital and Post Graduate Medical Institute Coimbatore, IndiaCollaborator
- SP Medical College, BikanerCollaborator
- Sree Chitra Tirual Institute for Sciences and Technology, KerelaCollaborator
- St. Stephen's Hospital, DelhiCollaborator
- Tirunelveli Medical College, Tirunelveli, IndiaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.